Hearing Loss in Beta-Thalassemia: Systematic Review

Tartaglione, Immacolata; Carfora, Roberta; Brotto, Davide; Barillari, Maria Rosaria; Costa, Giuseppe; Perrotta, Silverio; Manara, Renzo

doi:10.3390/jcm11010102

Cited by 10 publications

(23 citation statements)

References 54 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This complication has not been found to be related to age, sex, and ferritin level in many studies. However, Tartaglione's study reported a weak correlation between hearing loss, clinical phenotype, and iron chelator 37 …”

Section: Discussionmentioning

confidence: 97%

Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study

Faranoush,

Heydari

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsOne of the most common hemoglobinopathies globally related to blood transfusion and iron overload in the body is thalassemia syndrome. Increasing ferritin levels can cause severe damage to the patient's body organs. This study aims to evaluate the complications of iron overload on vital body organs in patients with transfusion‐dependent beta‐thalassemia.MethodsThis descriptive cross‐sectional study was performed in Iran University of Medical Sciences Hospitals on patients with a beta‐thalassemia major with frequent blood transfusions. To evaluate the effect of iron overload on vital body organs, hematologic and blood analysis, echocardiography with measurement of pulmonary artery pressure (PAP) and ejection fraction (EF) tests, bone densitometry, and audiometric tests were performed for all patients.ResultsOf the 1010 patients participating in this study, 497 (49%) were males, 513 were (51%) females aged 5–74 years, and the majority of participants (85%) were over 20 years old. This study demonstrated that increasing ferritin levels had no notable correlation with sex, cholesterol, low‐density lipoprotein, parathyroid hormone, T4, and aspartate aminotransferase. However, elevating ferritin levels had significant correlations with increasing triglyceride, phosphorus, thyroid stimulating hormone, alkaline phosphatase, alanine transaminase, and PAP levels, age, hearing disorders, splenectomy, osteoporosis, and decreasing high‐density lipoprotein, body mass index, calcium, and EF levels.ConclusionImprovement in beta‐thalassemia patients' survival and quality of life can be due to multidisciplinary care in a comprehensive unit through regular follow‐up and early complication detection.

show abstract

Section: Discussionmentioning

confidence: 97%

Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study

Faranoush,

Heydari

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…">Diagnosis of hearing loss was made after audiometry had been conducted. Excluding patients who had a diagnosis of anemia (ICD‐9‐CM 280‐285) and/or nutritional deficiencies (ICD‐9‐CM 260‐269) because these diagnoses may also affect the risk of hearing loss 33,34 …”

Section: Methodsmentioning

confidence: 99%

Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study

Tseng

2023

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To compare the risk of hearing loss with regard to metformin exposure. Study Design Retrospective cohort. Setting Taiwan's National Health Insurance database. Methods We enrolled 292,071 ever users and 18,200 never users of metformin with new‐onset diabetes mellitus from 1999 to 2005 and followed them for hearing loss from January 1, 2006, to December 31, 2011. Hazard ratios (HRs) weighted by propensity score were estimated. Results Hearing loss was newly diagnosed in 10,085 ever users and 1072 never users. Their respective incidence rates (per 100,000 person‐years) were 738.09 and 1366.83. The HR comparing ever‐to‐never users was 0.534 (95% confidence interval [CI]: 0.501‐0.569]. The HR (95% CI) for the first (<27.07 months), second (27.07‐59.13 months), and third (>59.13 months) tertiles of cumulative duration of metformin therapy were 0.912 (0.852‐0.975), 0.544 (0.508‐0.582), and 0.275 (0.255‐0.295), respectively; and were 0.900 (0.841‐0.962), 0.531 (0.496‐0.569), and 0.293 (0.273‐0.315), respectively, for the first (<796.70 g), second (796.70‐2020.15 g), and third (>2020.15 g) tertiles of cumulative dose. The magnitude of risk reduction became more remarkable in corresponding to the increasing tertiles of the defined daily dose prescribed. Subtype analyses suggested that the risk reduction was more significant for sensorineural than conductive hearing loss. Findings derived from a propensity score‐matched cohort did not substantially change the conclusions, and the risk reduction for mixed hearing loss was not statistically significant in the matched cohort as significantly observed in the unmatched cohort. Conclusion The risk of hearing loss is reduced in a dose‐response pattern in patients who use metformin.

show abstract

“…Despite high prevalence of deferasirox consumption and numerous studies accessible in the literature, the true scenarios of visual and auditory complications in beta-thalassemia remain fairly inaccurate. In addition, the findings are markedly heterogeneous and inconsistent, with prevalence rates ranging from no visual and auditory disorders to visual and hearing impairment in patients (6,(8)(9)(10). The present study aimed to monitor visual complications such as color blindness, visual acuity change, cataracts, glaucoma, and retinal disorders, as well as auditory complications such as sensorineural hearing loss, tinnitus, and deafness which are the results of deferasirox consumption.…”

Section: Introductionmentioning

confidence: 98%

“…Several case reports reported an association between the onset of chelation therapy and occurrence of ocular symptoms (7)(8)(9). Also, auditory disorders occur during treatment with these agents for an extended period at high doses and in patients with augmented ferritin levels (7,10,11). Over the last few decades, there have been dramatic developments in survival for patients with thalassemia major due in large measure to enhanced iron chelators.…”

Section: Introductionmentioning

confidence: 99%

Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia

Poosheshdoost¹,

Faraji²,

Zeinali³

et al. 2022

IJPHO

View full text Add to dashboard Cite

Background: Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. Materials and Methods: This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron chelator consumption admitted to the 17 Shahrivar Hospital and the Besat Clinic in Rasht, Iran. All the patients were examined for visual and auditory complications caused by deferasirox in 2019. A checklist of the patients' demographical and clinical data was recorded. Data analysis was done with SPSS and reported by descriptive statistics. Then, Fisher's exact test was performed to examine the association between visual and auditory disorders and the use of deferasirox in terms of disease-related variables including age, sex, age of onset of using chelator, drug use duration, drug dosage, and mean 6-months serum ferritin levels (P <0.05 as the significance level). Results: Of a total of 156 patients, 103 (66%) were female and 56 (35.9%) were 20-30 years of age. The prevalence of visual acuity change was 0.6%, and the prevalence of sensorineural hearing loss was 1.3%. There was only one female with the visual disorder decreasing to 9/10 and with a dose of 31-40 mg/kg/day with an average of 1000-2500 ng/ml six-month ferritin. Also, two females with hearing impairment were confirmed with a dose of ≤30 mg/kg/day, and an average of ≤1000 ng/ml six-month ferritin. The Fisher's exact test results showed no significant relationship between visual and auditory disorders with the use of deferasirox in terms of disease-related variables (p>0.05). Conclusion: The study's findings showed no significant relationship between visual and auditory disorders with deferasirox consumption. The results indicated the safety of deferasirox regarding visual and auditory side effects. More studies are required to confirm the findings.

show abstract

Hearing Loss in Beta-Thalassemia: Systematic Review

Cited by 10 publications

References 54 publications

Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study

Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study

Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study

Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia

Contact Info

Product

Resources

About